DM21
DM21 is a next-generation linker-payload that combines a maytansinoid microtubule-disrupting payload with a stable tripeptide linker. DM21 is conjugated with a humanized antibody against ADAM9 to obtain IMGC936[1].
Product Specifications
CAS Number
2243689-80-5
UNSPSC
12352203
Hazard Statement
H302, H315, H319, H335
Target
Drug-Linker Conjugates for ADC; Microtubule/Tubulin
Type
ADC Related
Related Pathways
Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Cytoskeleton
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/dm21.html
Purity
99.34
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
C[C@]12[C@@]([C@@H]([C@]3([H])C[C@]([C@@H](/C=C/C=C(CC4=CC(N(C(C[C@@H]2OC([C@H](C)N(C)C(CCCCCSCNC([C@H](C)NC([C@@H](C)NC([C@H](C)NC(CCCCCN5C(C=CC5=O)=O)=O)=O)=O)=O)=O)=O)=O)C)=C(C(OC)=C4)Cl)\C)OC)(NC(O3)=O)O)C)([H])O1
Molecular Formula
C58H83ClN8O16S
Molecular Weight
1215.84
Precautions
H302, H315, H319, H335
References & Citations
[1]Olga Ab, et al. Abstract 1841: IMGC936, an investigational ADAM9-targeting antibody drug conjugate, is active against patient-derived ADAM9-expressing xenograft models Free. Cancer Res (2021) 81 (13_Supplement) : 1841.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
ADC Related
Clinical Information
No Development Reported
Isoform
Maytansinoids
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
